- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00033267
CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma
A Phase II Study of CCI-779 in Previously Treated Patients With Mantle Cell Non-Hodgkin's Lymphoma
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
OBJECTIVES:
I. Determine the objective responses in patients with previously treated mantle cell non-Hodgkin's lymphoma treated with CCI-779.
II. Determine the toxic effects of this drug in these patients. III. Determine whether this drug inhibits cell proliferation pathways in these patients.
OUTLINE:
Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with stable disease receive a maximum of 6 courses. Patients with partial response receive a maximum of 12 courses. Patients with complete response (CR) receive 2 additional courses beyond CR.
Patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and then annually for 2 years.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Minnesota
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- North Central Cancer Treatment Group
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Histologically confirmed mantle cell non-Hodgkin's lymphoma (MCL)
- Relapsed, refractory, or stable disease after prior chemotherapy, radiotherapy, or immunotherapy
Unidimensionally measurable lymph node or lesion
- At least 2.0 cm by CT scan or MRI OR at least 1.5 cm by physical exam
One of the following measurement parameters may be used:
- Splenic enlargement may be used as a measurement parameter if spleen is palpable at least 3.0 cm across left costal margin
- Malignant lymphocytosis may be used as a measurement parameter if absolute lymphocyte count is at least 5,000/mm^3
- No known CNS involvement (parenchymal mass or leptomeningeal involvement)
- Performance status - ECOG 0-2
- At least 3 months
- See Disease Characteristics
- Absolute neutrophil count ≥ 1,000/mm^3
- Platelet count ≥ 75,000/mm^3
- Hemoglobin ≥ 8 g/dL
- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
- Direct bilirubin ≤ 1.5 times ULN
- AST ≤ 3 times ULN (5 times ULN if liver metastases are present)
- Creatinine ≤ 2 times ULN
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
- Cholesterol ≤ 350 mg/dL
- Triglycerides ≤ 400 mg/dL
- HIV negative
- No other active malignancy requiring treatment or that would preclude study participation
- No other concurrent uncontrolled illness
- No ongoing or active infection
- No psychiatric illness or social situation that would preclude study participation
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after study participation
- See Disease Characteristics
- Prior high-dose therapy with stem cell transplantation allowed
- At least 7 days since prior immunotherapy or other non-myelosuppressive biologic response modifiers
- See Disease Characteristics
- See Biologic therapy
- At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas or mitomycin)
- No other concurrent chemotherapy for MCL
- Concurrent corticosteroids for adrenal insufficiency allowed
- See Disease Characteristics
- At least 3 weeks since prior radiotherapy
- No concurrent radiotherapy for MCL
- Any number of prior treatments allowed
- No other concurrent investigational or commercial agents for MCL
- No concurrent drugs that induce cytochrome p450 (e.g., carbamazepine, phenobarbital, phenytoin, ketoconazole, diltiazem, rifampin, terfenadine, cisapride, astemizole, or pimozide)
- No concurrent immunosuppressive therapies
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Treatment
Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients with stable disease receive a maximum of 6 courses.
Patients with partial response receive a maximum of 12 courses.
Patients with CR receive 2 additional courses beyond CR.
|
Gegeben IV
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Proportion of patients who achieve a confirmed CR or PR during the first 24 weeks of treatment defined by the International Workshop criteria
Zeitfenster: Up to 24 weeks
|
The proportion will be evaluated separately for each dose group.
The proportion of patients who achieve a confirmed CR or PR, or success, will be estimated by the number of successes divided by the total number of evaluable patients.
Ninety-five percent confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner.
|
Up to 24 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Progressionsfreies Überleben
Zeitfenster: Zeit von der Registrierung bis zur Progression oder Tod aus irgendeinem Grund, bewertet bis zu 5 Jahren
|
Die Verteilung des progressionsfreien Überlebens wird nach der Methode von Kaplan-Meier geschätzt.
|
Zeit von der Registrierung bis zur Progression oder Tod aus irgendeinem Grund, bewertet bis zu 5 Jahren
|
Time to progression
Zeitfenster: Time from registration to the time of progression, assessed up to 5 years
|
The distribution of time to progression will be estimated using the method of Kaplan-Meier.
|
Time from registration to the time of progression, assessed up to 5 years
|
Overall survival
Zeitfenster: Time from registration to death due to any cause, assessed up to 5 years
|
The distribution of overall survival will be estimated using the method of Kaplan-Meier.
|
Time from registration to death due to any cause, assessed up to 5 years
|
Duration of response
Zeitfenster: From the date of study registration until the date of progression in the subset of patients who respond, assessed up to 5 years
|
From the date of study registration until the date of progression in the subset of patients who respond, assessed up to 5 years
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Stephen Ansell, North Central Cancer Treatment Group
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Neubildungen
- Lymphoproliferative Erkrankungen
- Lymphatische Erkrankungen
- Immunproliferative Erkrankungen
- Lymphom
- Lymphom, Non-Hodgkin
- Lymphom, Mantelzelle
- Physiologische Wirkungen von Arzneimitteln
- Antiinfektiva
- Antineoplastische Mittel
- Immunsuppressive Mittel
- Immunologische Faktoren
- Antibakterielle Mittel
- Antibiotika, antineoplastische
- Antimykotika
- Sirolimus
Andere Studien-ID-Nummern
- NCI-2012-01870 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- U10CA025224 (US NIH Stipendium/Vertrag)
- NCCTG-N0186
- CDR0000069269
- N0186 (Andere Kennung: CTEP)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Rezidivierendes Mantelzell-Lymphom
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI); Genentech, Inc.RekrutierungDiffuses großzelliges B-Zell-Lymphom | Wiederkehrendes diffuses großzelliges B-Zell-Lymphom | Refraktäres diffuses großzelliges B-Zell-Lymphom | Primäres mediastinales (thymisches) großes B-Zell-Lymphom | Follikuläres Lymphom Grad 3b | Transformierte follikuläre Lymphe zu Diff Large B-Zell-Lymphom und andere BedingungenVereinigte Staaten
Klinische Studien zur Temsirolimus
-
Sheba Medical CenterStanley Medical Research InstituteUnbekanntSchizophrenie | Schizoaffektiven StörungIsrael
-
St. Joseph's Healthcare HamiltonPfizer; McMaster UniversityAbgeschlossenNierenzellkarzinomKanada
-
AVEO Pharmaceuticals, Inc.Abgeschlossen
-
Dana-Farber Cancer InstituteWyeth is now a wholly owned subsidiary of Pfizer; Millennium Pharmaceuticals...AbgeschlossenMultiples MyelomVereinigte Staaten
-
Children's Hospital Medical Center, CincinnatiZurückgezogenLymphom, B-Zell | Leukämie, B-ZelleVereinigte Staaten
-
Mathias Witzens-HarigCharite University, Berlin, Germany; Ludwig-Maximilians - University of Munich; Johann Wolfgang Goethe University Hospital und andere MitarbeiterUnbekanntDiffuses großzelliges B-Zell-LymphomDeutschland
-
New Mexico Cancer Care AllianceWyeth is now a wholly owned subsidiary of PfizerBeendetSarkomVereinigte Staaten
-
Wyeth is now a wholly owned subsidiary of PfizerPfizerAbgeschlossenNeoplasien der Brust
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Abgeschlossen
-
M.D. Anderson Cancer CenterAbgeschlossen